Natera highlights Allogene Therapeutics’ analysis from ALPHA3 trial

Natera (NTRA) highlighted Allogene Therapeutics’ (ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel, an investigational allogeneic anti-CD19 CAR T therapy, in first-line consolidation large B-cell lymphoma, LBCL. The interim analysis showed that 58.3% of MRD-positive patients treated with cema-cel achieved MRD clearance. In addition, at the Day-45 MRD assessment, plasma ctDNA levels decreased from baseline by a median of 97.7% in the cema-cel arm compared to a 26.6% median increase in the observation arm, suggesting molecular disease progression due to lack of intervention. These findings provide early evidence that cema-cel may help prevent or delay clinical relapse for LBCL patients with MRD.